Overview
- Phase IIa results published in June 2025 reported that patients on the 60 mg dose of rentosertib gained a mean 98.4 mL in forced vital capacity over 12 weeks while placebo patients lost 20.3 mL.
- A small study reported Monday found rentosertib reduced multiple biological aging clocks in 42 participants over a 12-week period, but the finding comes from a limited sample and short follow-up.
- Insilico launched a randomized, double-blind, placebo-controlled Phase III trial in July 2026 across roughly 47 centers in China with about 320 patients to confirm efficacy and safety.
- Rentosertib was designed by Insilico’s AI platforms to inhibit TNIK and acts as a senomorphic agent that modulates the senescence-associated secretory phenotype instead of killing senescent cells.
- Experts caution that aging clocks are not yet accepted surrogate endpoints and that multi-year, larger trials and deeper biomarker analysis are required before clinical or regulatory conclusions can be drawn.